EP
CLDX icon

Eversept Partners’s Celldex Therapeutics CLDX Stock Holding History

Eversept Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-191,600
Closed -$5.17M – 76
2022
Q2 		$5.17M Buy
+191,600
New +$5.56M 0.37% 46

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's CLDX Position: Q1 2026 in Review

Eversept Partners increased its Celldex Therapeutics (CLDX) stake by 25% in Q1 2026, buying an estimated $9.63M and bringing the position to 1,788,016 shares worth $56.7M. The position accounts for 2.99% of the portfolio, ranked #9.

Eversept Partners first reported a position in CLDX in Q2 2020 and has held it in 20 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Eversept Partners held 1,788,016 shares of Celldex Therapeutics worth $56.7M as of Q1 2026.
  • Eversept Partners bought 353,291 Celldex Therapeutics shares in Q1 2026, an estimated $9.63M.
  • Celldex Therapeutics made up 2.99% of Eversept Partners's portfolio in Q1 2026, its #9 holding.
  • Eversept Partners first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.